Mode
Text Size
Log in / Sign up

NF-kappaB, MAPK, JAK/STAT, and NLRP3 inflammasome pathways drive inflammation in carotid atherosclerosisInflammatory Pathways Linked to Carotid Atherosclerosis Stability

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that specific inflammatory pathways like NLRP3 and M1 macrophage dominance are key targets for precision therapy.

This narrative review explores the molecular mechanisms underlying carotid atherosclerosis, specifically focusing on the signaling pathways and immune cell dynamics that contribute to plaque instability. The authors synthesize findings regarding the hierarchical activation of NF-kappaB, MAPK, JAK/STAT, and the NLRP3 inflammasome as central drivers of the disease process.

Key findings highlight the expression of inflammatory mediators, including TNF-alpha, IL-1beta, and MMPs, as critical components of the inflammatory environment. Furthermore, the review notes an imbalance between pro-inflammatory M1 macrophages, Th1, and Th17 cells versus anti-inflammatory M2 macrophages and Tregs, which impacts plaque stability. These specific nodes are identified as potential targets for precision therapies rather than broad immunosuppression.

The authors acknowledge that this is not a systematic review and does not follow a formal systematic-search protocol. The review does not provide clinical trial data or specific evidence for any single therapeutic intervention. The findings are primarily mechanistic, and clinical application for specific treatments is not yet established.

How this fits prior evidence

This narrative review addresses the underlying mechanisms of carotid atherosclerosis by identifying specific inflammatory nodes. It complements the finding that Tongxinluo plus statins may improve carotid atherosclerosis markers, though that evidence has moderate to low certainty. While the current review focuses on molecular pathways like the NLRP3 inflammasome, the previously covered radiomics models provided a method for predicting stroke recurrence in a retrospective cohort.

This narrative review looked at the biological processes behind carotid atherosclerosis, which is the buildup of plaque in the carotid arteries. The review focused on how the body's immune system and inflammatory signals interact with these plaques.

Researchers identified several specific pathways, including NF-kB, MAPK, JAK/STAT, and the NLRP3 inflammasome. They also noted that certain proteins like TNF-alpha and IL-1beta are involved in the inflammatory process. A key finding was an imbalance between different types of immune cells. Specifically, there was an imbalance between pro-inflammatory cells and anti-inflammatory cells, which can affect how stable a plaque remains.

Because this is a narrative review and not a clinical trial, it does not provide evidence for any specific medication or treatment. The findings are currently used to help scientists identify specific targets for future precision therapies. These therapies would aim to stabilize high-risk plaques rather than using broad treatments.

What this means for you:
Specific inflammatory pathways and immune cell imbalances are linked to carotid plaque stability.

Common questions

What specific biological pathways are involved in carotid atherosclerosis?

The review identifies a hierarchical activation of several signaling pathways, including NF-kB, MAPK, JAK/STAT, and the NLRP3 inflammasome. These pathways are part of the inflammatory network that contributes to the development of carotid atherosclerosis.

How do immune cells affect the stability of artery plaques?

The research found an imbalance between different immune cell populations. Specifically, there is an imbalance between pro-inflammatory cells (like M1 macrophages, Th1, and Th17) and anti-inflammatory cells (like M2 macrophages and Tregs). This balance is linked to how stable a plaque remains.

Does this research suggest a specific new treatment for carotid atherosclerosis?

No, this study does not provide clinical trial data or evidence for any specific medication. It is a narrative review used to identify potential targets for future precision therapies to stabilize high-risk plaques.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundCarotid atherosclerosis (CAS; herein referring to carotid atherosclerotic disease, to be distinguished from carotid artery stenting, which shares the same abbreviation) is a primary driver of ischemic stroke, with inflammation playing a central role in its pathogenesis from plaque initiation to rupture. However, the complex regulatory network governing this inflammatory process remains to be fully elucidated.PurposeThis review comprehensively reviews the molecular and cellular inflammatory mechanisms underlying CAS, focusing on key signaling pathways, inflammatory mediators, and immune cell populations, to identify potential targets for therapeutic intervention. As a narrative review, it does not follow a formal systematic-search protocol.Key findingsWe delineate the hierarchical activation of core signaling cascades—including the central NF-κB pathway, the MAPK and JAK/STAT modules, and the NLRP3 inflammasome—which collectively orchestrate a pro-inflammatory milieu. This network drives the expression of critical mediators (e.g., TNF-α, IL-1β, MMPs) and sculpts the behavior of lesional immune cells. Specifically, the imbalance between pro-inflammatory M1 macrophages together with Th1/Th17 effector T cells, vs. anti-inflammatory M2 macrophages and Tregs emerges as a key determinant of plaque stability.Conclusionand Implications: The pathogenesis of CAS is governed by an intricate, multi-level inflammatory network. A detailed understanding of this network, particularly the crosstalk between signaling pathways and immune cell plasticity, provides a rationale for novel precision therapies. Targeting specific nodes within this network, rather than broad immunosuppression, holds promise for stabilizing high-risk plaques and reducing the burden of cerebrovascular events.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.